F5 appoints Dhananjay Ganjoo as MD for India, Saarc - Bengaluru News
by Maria Thomas | Updated Jun 29, 2020
Headquartered in Seattle, Washington, F5 powers applications from development through their entire lifecycle, across any multi-cloud environment.
In this role, Ganjoo will be responsible for driving F5's growth strategy in India and Saarc, establishing F5 as a leader in multi-cloud application services.
He will succeed Edgar Dias who was recently appointed to Regional Vice President of Channel and Partnerships for Asia Pacific.
"Dhananjay brings a wealth of industry and leadership experience with him, invaluable assets as we pursue our next phase of growth in India and Saarc," said Adam Judd, Senior Vice President, Asia Pacific, China and Japan, F5.
"India has always been an important market for F5 and we have a strategic opportunity to extend our multi-cloud application services to support the nation's digital transformation plans. We look forward to Dhananjay's leadership and expertise to strengthen our position in India."
Ganjoo joined F5 in 2018 and was responsible for building the company's Global System Integrators (GSI) business.
Prior to F5, he held leadership roles across leading enterprise and telecom organisations including, Nortel, Juniper Networks and Microsoft.
He also had an entrepreneurial stint where he founded Envoy Labs, which offered consultancy services to startups and SMBs.
Related Articles
- Optical Illusion Brain Test: If you have Sharp Eyes Find the Number 442 in 20 Secs
- London-based firm Nothing to release its Phone (2)
- Covid will continue to cause mini-waves, not become seasonal yet: Scientists
- Hackers offering crypto accounts for as low as $30 on darknet
- Reddit's new feature to allow users to share its content on other platforms
- Surgical masks can help kids fight respiratory infections: Study
- LinkedIn's new AI feature to write messages to hiring team
- Microsoft introduces Xbox Game Pass' new Friend Referral programme
- Disbursed over Rs 31 cr in claims to delivery partners in FY22-23: Swiggy
- India emerging as favourable destination for clinical trials: Report